Skip to main content

LabCorp, OmniSeq Sign Distribution Deal

NEW YORK (GenomeWeb) – OmniSeq and Laboratory Corporation of America have signed an exclusive distribution agreement for OmniSeq's immune profiling and pan-cancer next-generation sequencing tests.

In addition, LabCorp will also participate in OmniSeq's Series B financing round, the proceeds of which will be used to conduct ongoing retrospective and prospective clinical trials. LabCorp Diagnostics CSO Marcia Eisenberg will join OmniSeq’s board of directors.

OmniSeq is a molecular diagnostics subsidiary of the Roswell Park Cancer Institute. Both its Immune Report Card test and OmniSeq Comprehensive test have received approval from New York State's Clinical Laboratory Evaluation Program. The Immune Report Card assay is designed to help oncologists make treatment decisions regarding immune checkpoint inhibitors by analyzing microsatellite instability, mutational burden, and performing RNA-seq. OmniSeq Comprehensive is a 144-gene pan-cancer NGS assay designed to guide treatment decisions.

Under the terms of the agreement with LabCorp, the assays will be performed by OmniSeq and offered in the US through Integrated Oncology and globally through Covance Drug Development.

"By combining OmniSeq's technology with LabCorp's unmatched companion diagnostics expertise, we will bring advances in precision medicine to many more physicians and biopharmaceutical partners," Eisenberg said in a statement.